These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 29395121)

  • 1. Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy.
    Grossi F; Genova C; Rijavec E; Barletta G; Biello F; Dal Bello MG; Meyer K; Roder J; Roder H; Grigorieva J
    Lung Cancer; 2018 Mar; 117():64-69. PubMed ID: 29395121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
    Buttigliero C; Shepherd FA; Barlesi F; Schwartz B; Orlov S; Favaretto AG; Santoro A; Hirsh V; Ramlau R; Blackler AR; Roder J; Spigel D; Novello S; Akerley W; Scagliotti GV
    Oncologist; 2019 Jun; 24(6):e251-e259. PubMed ID: 30139835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the VeriStrat
    Gadgeel S; Goss G; Soria JC; Felip E; Georgoulias V; Lu S; Cobo M; Syrigos K; Lee KH; Göker E; Guclu SZ; Isla D; Morabito A; Dupuis N; Bühnemann C; Krämer N; Solca F; Ehrnrooth E; Ardizzoni A
    Lung Cancer; 2017 Jul; 109():101-108. PubMed ID: 28577938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.
    Peters S; Stahel RA; Dafni U; Ponce Aix S; Massutí B; Gautschi O; Coate L; López Martín A; van Heemst R; Berghmans T; Meldgaard P; Cobo Dols M; Garde Noguera J; Curioni-Fontecedro A; Rauch D; Mark MT; Cuffe S; Biesma B; van Henten AMJ; Juan Vidal Ó; Palmero Sanchez R; Villa Guzmán JC; Collado Martin R; Peralta S; Insa A; Summers Y; Láng I; Horgan A; Ciardiello F; de Hosson S; Pieterman R; Groen HJM; van den Berg PM; Zielinski CC; Chittazhathu Kurian Kuruvilla Y; Gasca-Ruchti A; Kassapian M; Novello S; Torri V; Tsourti Z; Gregorc V; Smit EF;
    J Thorac Oncol; 2017 Apr; 12(4):752-762. PubMed ID: 28017787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.
    Grossi F; Rijavec E; Genova C; Barletta G; Biello F; Maggioni C; Burrafato G; Sini C; Dal Bello MG; Meyer K; Roder J; Roder H; Grigorieva J
    Br J Cancer; 2017 Jan; 116(1):36-43. PubMed ID: 27898657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.
    Carbone DP; Ding K; Roder H; Grigorieva J; Roder J; Tsao MS; Seymour L; Shepherd FA
    J Thorac Oncol; 2012 Nov; 7(11):1653-60. PubMed ID: 23059783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy.
    Lee SM; Upadhyay S; Lewanski C; Falk S; Skailes G; Woll PJ; Hatton M; Lal R; Jones R; Toy E; Rudd R; Ngai Y; Edwards A; Hackshaw A
    Eur J Cancer; 2019 Oct; 120():86-96. PubMed ID: 31499384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients.
    Fidler MJ; Fhied CL; Roder J; Basu S; Sayidine S; Fughhi I; Pool M; Batus M; Bonomi P; Borgia JA
    BMC Cancer; 2018 Mar; 18(1):310. PubMed ID: 29558888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528.
    Gautschi O; Dingemans AM; Crowe S; Peters S; Roder H; Grigorieva J; Roder J; Zappa F; Pless M; Brutsche M; Baty F; Bubendorf L; Hsu Schmitz SF; Na KJ; Carbone D; Stahel R; Smit E
    Lung Cancer; 2013 Jan; 79(1):59-64. PubMed ID: 23122759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors.
    Lazzari C; Spreafico A; Bachi A; Roder H; Floriani I; Garavaglia D; Cattaneo A; Grigorieva J; Viganò MG; Sorlini C; Ghio D; Tsypin M; Bulotta A; Bergamaschi L; Gregorc V
    J Thorac Oncol; 2012 Jan; 7(1):40-8. PubMed ID: 21964534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib.
    Kuiper JL; Lind JS; Groen HJ; Roder J; Grigorieva J; Roder H; Dingemans AM; Smit EF
    Br J Cancer; 2012 Nov; 107(11):1820-5. PubMed ID: 23079575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VeriStrat: a prognostic and/or predictive biomarker for advanced lung cancer patients?
    Molina-Pinelo S; Pastor MD; Paz-Ares L
    Expert Rev Respir Med; 2014 Feb; 8(1):1-4. PubMed ID: 24308656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D deficiency is associated with a poor prognosis in advanced non-small cell lung cancer patients treated with platinum-based first-line chemotherapy.
    Ma K; Xu W; Wang C; Li B; Su K; Li W
    Cancer Biomark; 2017; 18(3):297-303. PubMed ID: 27983538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis.
    Nelson RE; Stenehjem D; Akerley W
    Lung Cancer; 2013 Dec; 82(3):461-8. PubMed ID: 24074609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis.
    Leal TA; Argento AC; Bhadra K; Hogarth DK; Grigorieva J; Hartfield RM; McDonald RC; Bonomi PD
    Curr Med Res Opin; 2020 Sep; 36(9):1497-1505. PubMed ID: 32615813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
    Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
    Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
    Joerger M; Baty F; Früh M; Droege C; Stahel RA; Betticher DC; von Moos R; Ochsenbein A; Pless M; Gautschi O; Rothschild S; Brauchli P; Klingbiel D; Zappa F; Brutsche M
    Lung Cancer; 2014 Aug; 85(2):306-13. PubMed ID: 24928469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of bulky mediastinal lymph nodes (N2>2.5 cm) in patients with locally advanced non-small-cell lung cancer (LA-NSCLC) treated with platinum-based induction chemotherapy.
    Maurel J; Martinez-Trufero J; Artal A; Martin C; Puertolas T; Zorrrilla M; Herrero A; Antón A; Rosell R
    Lung Cancer; 2000 Nov; 30(2):107-16. PubMed ID: 11086204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24.
    Bar J; Ding K; Zhao H; Han L; Laurie SA; Seymour L; Addison CL; Shepherd FA; Goss GD; Dimitroulakos J; Bradbury PA
    Clin Lung Cancer; 2015 Nov; 16(6):e189-201. PubMed ID: 26081815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic Treatment Patterns With Advanced or Recurrent Non-small Cell Lung Cancer in Japan: A Retrospective Hospital Administrative Database Study.
    Wang F; Mishina S; Takai S; Le TK; Ochi K; Funato K; Matsuoka S; Ohe Y
    Clin Ther; 2017 Jun; 39(6):1146-1160. PubMed ID: 28527959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.